ESPR
Esperion Therapeutics Inc
NASDAQ: ESPR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$2.00
+4.71% today
Updated 2026-04-30
Market cap
$491.64M
P/E ratio
—
P/S ratio
1.22x
EPS (TTM)
$-0.11
Dividend yield
—
52W range
$1 – $4
Volume
6.1M
Esperion Therapeutics Inc (ESPR) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 1999 | 2000 | 2001 | 2002 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $2000.00 | — | — | — | — | $4.98B | $0.00 | $0.00 | $0.00 | $0.00 | $184.47M | $148.36M | $227.55M | $78.45M | $75.47M | $116.33M | $332.31M | $403.13M |
| Revenue growth (YoY) | — | — | -100.0% | — | — | — | — | -100.0% | — | — | — | — | -19.6% | +53.4% | -65.5% | -3.8% | +54.1% | +185.7% | +21.3% |
| Cost of revenue | $683223.00 | $786000.00 | — | — | — | — | $0.00 | $0.00 | $236000.00 | $252000.00 | $258000.00 | $171.49M | $175.61M | $2.39M | $14.22M | $26.97M | $43.27M | $68.60M | $129.22M |
| Gross profit | $-683223.00 | $-784000.00 | — | — | — | — | $4.98B | $0.00 | $-236000.00 | $-252000.00 | $-258000.00 | $184.47M | $148.36M | $225.16M | $64.23M | $48.51M | $73.07M | $263.71M | $273.91M |
| Gross margin | — | -39200.0% | — | — | — | — | 100.0% | — | — | — | — | 100.0% | 100.0% | 98.9% | 81.9% | 64.3% | 62.8% | 79.4% | 67.9% |
| R&D | $8.48M | $21.79M | $21.45M | $21.99M | $7.81M | $8.00M | $16.01M | $25.30M | $29.80M | $57.87M | $147.60M | $171.49M | $175.61M | $146.94M | $105.97M | $118.93M | $86.11M | $46.24M | $47.85M |
| SG&A | — | — | — | — | $2.36M | $2.21M | $6.74M | $10.92M | $20.24M | $18.28M | $21.38M | $33.10M | $65.85M | $180.31M | $171.28M | $97.78M | $126.92M | $137.57M | $165.79M |
| Operating income | $-12.37M | $-27.57M | $-27.32M | $-27.95M | $-10.16M | $-10.20M | $-22.76M | $-36.22M | $-50.04M | $-76.15M | $-168.98M | $-204.59M | $-93.10M | $-121.40M | $-226.73M | $-179.50M | $-155.56M | $54.40M | $60.27M |
| Operating margin | — | -1378600.0% | — | — | — | — | -0.5% | — | — | — | — | -110.9% | -62.8% | -53.3% | -289.0% | -237.8% | -133.7% | 16.4% | 15.0% |
| EBITDA | $-11.69M | $-25.52M | $-26.80M | $-27.21M | $-10.06M | $-10.12M | $-22.69M | $-36.06M | $-49.03M | $-74.35M | $-166.53M | $-204.32M | $-88.73M | $-120.33M | $-222.14M | $-176.35M | $-150.11M | $7.57M | $60.27M |
| EBITDA margin | — | -1276100.0% | — | — | — | — | -0.5% | — | — | — | — | -110.8% | -59.8% | -52.9% | -283.2% | -233.7% | -129.0% | 2.3% | 15.0% |
| EBIT | $-11.00M | $-23.47M | $-24.79M | $-25.92M | $-10.24M | $-10.26M | $-22.76M | $-36.22M | $-49.26M | $-74.60M | $-166.79M | $-204.59M | $-89.05M | $-120.88M | $-222.75M | $-176.85M | $-150.27M | $7.51M | $60.17M |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $577157.00 | $1.49M | $936580.00 | $270000.00 | $520000.00 | $376000.00 | $198000.00 | $100000.00 | $8.12M | $22.67M | $46.35M | $56.81M | $58.98M | $59.25M | $84.60M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-10.67M | $-27.58M | $-24.93M | $-28.73M | $-10.82M | $-11.74M | $-26.09M | $-36.38M | $-49.78M | $-74.98M | $-166.99M | $-201.81M | $-97.17M | $-143.55M | $-269.11M | $-233.66M | $-209.25M | $-51.74M | $-22.68M |
| Net income growth (YoY) | — | -158.4% | +9.6% | -15.2% | +62.3% | -8.5% | -122.2% | -39.4% | -36.9% | -50.6% | -122.7% | -20.9% | +51.9% | -47.7% | -87.5% | +13.2% | +10.4% | +75.3% | +56.2% |
| Profit margin | — | -1378800.0% | — | — | — | — | -0.5% | — | — | — | — | -109.4% | -65.5% | -63.1% | -343.0% | -309.6% | -179.9% | -15.6% | -5.6% |